About
Here you will find summaries of all the latest publications on lupus, focusing on those covering treatments, recommendations and other topics that may influence clinical practice.
Latest Updates
All ▼
![](https://lupus-forum.com/storage/u0uYGMaLPbVi2m2ecM87jv93UsUdpwx570x42cYe.png)
Lupus Therapy Essentials 2024 Update
![](https://lupus-forum.com/storage/Walxoinl6IAK3bAYhqxPMVv5Z8zLLtlAwlTxOfEq.png)
World Kidney Day 2024
![Nature Logo](https://lupus-forum.com/storage/IP6wt54Aauqz5wXvhJNbKVro5geQeCVDpCAzlwB9.png)
Researchers from Trinity College Dublin establish a link between fumarate hydratase and inflammatory macrophages, identifying a potential future treatment pathway for lupus.
![Publication thumbnail: Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial](https://lupus-forum.com/storage/uqEne0QOCnsLW7tzmCgHkG9fR7Ns3kGyaxOwV2gR.jpg)
Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial
![Publication thumbnail: Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study](https://lupus-forum.com/storage/OXFgBoaGh331reG2g0KuFrFkZre0tUO3B2AW6yRf.jpg)
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
![Publication thumbnail: Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis](https://lupus-forum.com/storage/CT5XXIyQAETXuBVeIoY9FcSgNOo3U45uQPKVh04B.jpg)
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis
![Publication thumbnail: Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement](https://lupus-forum.com/storage/Ra7GNI4veFthRMY4w6GMktqx4UeRCD0Ya6s3OTeJ.jpg)
Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement
![Publication thumbnail: Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)](https://lupus-forum.com/storage/B9kzsYsb1OlVMWRADSdiY7WT9Cx1Ws1yg8I6t9Ef.jpg)
Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)
![Publication thumbnail: SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort](https://lupus-forum.com/storage/x4duD43yjbcXNLmlkkp4FxlK6t1sWc5azZYmhNLL.jpg)
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
![Publication thumbnail: Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials](https://lupus-forum.com/storage/chInYzuNyWm4ptTWZToWbfU2JFSZIJ3WXjeO9eKd.jpg)
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials
![Publication thumbnail: TYK2: An emerging therapeutic target in rheumatic disease](https://lupus-forum.com/storage/sI5BI40mdL9IysrTlk6p6agf5pQjtQrPI2sMioQo.jpg)
TYK2: An emerging therapeutic target in rheumatic disease
![Publication thumbnail: Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis](https://lupus-forum.com/storage/WkRtvTtCodscTNBsNTe0QktNRzSFe2J2xeD4IqKA.jpg)
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis
![Publication thumbnail: Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study](https://lupus-forum.com/storage/spVje1l8lO7WnUP9RKn6NokCybLGs7fKGD91yvGZ.jpg)
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study
![Publication thumbnail: Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up](https://lupus-forum.com/storage/oO0tTMJehGf6RPwGYzsjNA4OcyxdRtBkBDF7gKfL.jpg)
Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up
![Publication thumbnail: CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up](https://lupus-forum.com/storage/jgNkGD8YSErcXadlyugUSDMDVwYdbX4chctR2Wqu.jpg)
CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up
![Publication thumbnail: Evaluation of RNase Therapy in Systemic Lupus Erythematosus: A Randomised Phase 2a Clinical Trial of RSLV-132](https://lupus-forum.com/storage/2OdC5WBElMXkcjN6hsi4QX59UjZAoJsLWIfeOlGt.jpg)
Evaluation of RNase Therapy in Systemic Lupus Erythematosus: A Randomised Phase 2a Clinical Trial of RSLV-132
![Publication thumbnail: Smith-specific regulatory T cells halt the progression of lupus nephritis](https://lupus-forum.com/storage/VXfnNjTocDu71AluVpU90SgsElVMa3YVbUZyUEl9.jpg)
Smith-specific regulatory T cells halt the progression of lupus nephritis
![Publication thumbnail: Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial](https://lupus-forum.com/storage/fx7or29FG26ELqpHR9TnK0IcqAhc0FgqFrKVxknw.jpg)
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial
![Publication thumbnail: Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus](https://lupus-forum.com/storage/4BEKaNJjNcx8EZfEpod2ZnfKmBI7h0myqgVjdf2k.jpg)
Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus
![Publication thumbnail: Predictors of Renal Flares in Systemic Lupus Erythematosus: A Post-hoc Analysis of Four Phase III Clinical Trials of Belimumab](https://lupus-forum.com/storage/tFbcW9j3rTzzWNmpZaFVGkPjJ5lX5nfYlPzPHQKz.jpg)
Predictors of Renal Flares in Systemic Lupus Erythematosus: A Post-hoc Analysis of Four Phase III Clinical Trials of Belimumab
![Publication thumbnail: Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort](https://lupus-forum.com/storage/FbE5hkDo3gPboM5UelhH1SYvfdPQNcc9zv0t9UDQ.jpg)
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
![Publication thumbnail: Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial](https://lupus-forum.com/storage/zLLk5HgdgGBDC5JR3YORQSofXzz8XcXjcokD50hF.jpg)
Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
![Publication thumbnail: Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study](https://lupus-forum.com/storage/ydzx8NJludgCvLjERcM3tQdRCLODYiDhOaSoTGoF.jpg)
Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study
![Publication thumbnail: Telitacicept in Patients with Active Systemic Lupus Erythematosus: Results of A Phase 2b, Randomised, Double-blind, Placebo-controlled Trial](https://lupus-forum.com/storage/88KRK72mU8yPkIK9X5hthzWs2sJor1FmqDVrCd60.jpg)
Telitacicept in Patients with Active Systemic Lupus Erythematosus: Results of A Phase 2b, Randomised, Double-blind, Placebo-controlled Trial
![Publication thumbnail: Burden of Systemic Lupus Erythematosus in Clinical Practice: Baseline Data from the SLE Prospective Observational Cohort Study (SPOCS) by Interferon Gene Signature](https://lupus-forum.com/storage/nxyPSwQxmYHLiJFxhhddfKJl3lenh4ES2MoU6q98.jpg)
Burden of Systemic Lupus Erythematosus in Clinical Practice: Baseline Data from the SLE Prospective Observational Cohort Study (SPOCS) by Interferon Gene Signature
![Publication thumbnail: Assessment and Personalised Advice for Fatigue in Systemic Lupus Erythematosus Using an Innovative Digital Tool: The Lupus Expert System for the Assessment of Fatigue (LEAF) Study](https://lupus-forum.com/storage/DdvgK0Kc3Ld6XDjJ9y8O9cZt5fF0TNsxQPjXpYJb.jpg)
Assessment and Personalised Advice for Fatigue in Systemic Lupus Erythematosus Using an Innovative Digital Tool: The Lupus Expert System for the Assessment of Fatigue (LEAF) Study
![Publication thumbnail: Emerging Immunotherapeutic Strategies for Cutaneous Lupus Erythematosus: An Overview of Recent Phase 2 and 3 Clinical Trials](https://lupus-forum.com/storage/QPS7Tpap52U2oebBO7tX0MT1jve945aU4WcDVbo4.jpg)
Emerging Immunotherapeutic Strategies for Cutaneous Lupus Erythematosus: An Overview of Recent Phase 2 and 3 Clinical Trials
![Publication thumbnail: EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update](https://lupus-forum.com/storage/wauEhF43HBTpgCDbivbWP9FkR0i658H4Rk254NWG.jpg)
EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update
![Publication thumbnail: Impact of Low Disease Activity, Remission, and Complete Remission on Flares Following Tapering of Corticosteroids and Immunosuppressive Therapy in Patients with Systemic Lupus Erythematous: A Multinational Cohort Study](https://lupus-forum.com/storage/TR75m84T7Q3M0M5MqO46ZBYAbd44whcXNT1oI7hR.jpg)
Impact of Low Disease Activity, Remission, and Complete Remission on Flares Following Tapering of Corticosteroids and Immunosuppressive Therapy in Patients with Systemic Lupus Erythematous: A Multinational Cohort Study
![Publication thumbnail: Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center](https://lupus-forum.com/storage/pnsars3VANBTSrl3TwP2XTzQ7Dh5dzBHV33rfsm1.jpg)
Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center
![Publication thumbnail: Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases](https://lupus-forum.com/storage/7zlZmwgMeyFyiGA1VLhQ8HF8C5RGU7QvIjQcUPcQ.jpg)
Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases
![Publication thumbnail: Effect of Belimumab on Kidney-related Outcomes in Patients with Lupus Nephritis: Post Hoc Subgroup Analyses of the Phase 3 BLISS-LN Trial](https://lupus-forum.com/storage/5w4uGBaaI6QVWNZvHAIkgqzOrNEoGBS44KDEj2tg.jpg)